EZH2 and cancer: Emerging therapies for SCCOHT are rapidly moving from bench to bedside: EZH2 inhibitors (GSK126, EPZ-6438) exploit SMARCA4 loss to reactivate tumor-suppressive chromatin programs; the multi-kinase inhibitor ponatinib, identified by high-throughput screens, suppresses FGFR/PDGFR-driven signaling in SMARCA4-deficient cells; meanwhile, immune-checkpoint blockade (PD-1/PD-L1 inhibitors) is being combined with anti-angiogenic agents and CDK4/6 inhibitors.[23–25] In addition, immune checkpoint inhibitors have shown great potential in treating various cancers, including ovarian cancer.